Skip to main content

 Related scientific articles (all)

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Authors : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

Tumor dormancy at bedside: A late awakening.

Authors : Demicheli R, Desmedt C, Piccart-Gebhart M, Biganzoli E
Year : 2019
Journal : Breast
Volume : 45
Pages : 61-63

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

Authors : Lambertini M, Richard F, Nguyen B, Viglietti G, Villarreal-Garza C
Year : 2019
Journal : Clin Med Insights Reprod Health
Volume : 13
Pages : 1179558119828393

Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.

Authors : Nguyen B, Veys I, Leduc S, Bareche Y, Majjaj S, Brown DN, Boeckx B, Lambrechts D, Sotiriou C, Larsimont D, Desmedt C
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 742-746

ESR1 mutations in metastatic lobular breast cancer patients.

Authors : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 9

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Authors : Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 1434

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Authors : Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 25

pAKT pathway activation is associated with <i>PIK3CA</i> mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.

Authors : Sonnenblick A, Venet D, Brohée S, Pondé N, Sotiriou C
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 7

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Authors : Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 365-373

The circular RNome of primary breast cancer.

Authors : Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies HR, Staaf J, Van de Vijver MJ, Richardson AL, Macgrogan G, Salgado R, Van den Eynden GGGM, Purdie CA, Thompson AM, Caldas C, Span PN, Sweep FCGJ, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Paradiso A, Eyfjord J, Broeks A, Vincent-Salomon A, Futreal AP, Knappskog S, King T, Viari A, Børresen-Dale AL, Stunnenberg HG, Stratton M, Foekens JA, Sieuwerts AM, Martens JWM
Year : 2019
Journal : Genome Res
Volume : 29
Pages : 356-366

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Authors : Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, OMeara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, vant Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, Van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR
Year : 2019
Journal : Nature

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1018

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1180

Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Authors : Brandão M, Coens C, Ignatiadis M
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1677-1681

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Authors : Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart-Gebhart M, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Year : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 559-569

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Authors : Brandão M, Caparica R, Eiger D, de Azambuja E
Year : 2019
Journal : Ann Oncol
Volume : 30 Suppl 10
Pages : x27-x42

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.

Authors : Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, Richard F, Delorenzi M, Sotiriou C, Desmedt C, Lorusso G, Rüegg C
Year : 2019
Journal : Oncogene
Volume : 38
Pages : 2814-2829

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

Authors : Nederlof I, De Bortoli D, Bareche Y, Nguyen B, de Maaker M, Hooijer GKJ, Buisseret L, Kok M, Smid M, Van den Eynden GGGM, Brinkman AB, Hudecek J, Koster J, Sotiriou C, Larsimont D, Martens JWM, Van de Vijver MJ, Horlings HM, Salgado R, Biganzoli E, Desmedt C
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 151

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Authors : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Year : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Systemic treatment of patients with early breast cancer: recent updates and state of the art.

Authors : Caparica R, Brandão M, Piccart-Gebhart M
Year : 2019
Journal : Breast
Volume : 48 Suppl 1
Pages : S7-S20